SCHEMBL4536243

SCHEMBL4536243

Brc1ccc2ccnnc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
BACE1 P56817 2/20 0.50
PABPC1 P11940 1/20 0.42
CYP2A6 P11509 1/20 0.38
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
NOS1 P29475 2/20 0.35
METAP2 P50579 2/20 0.35
DYRK1A Q13627 1/20 0.35
PLAU P00749 2/20 0.35
PLG P00747 1/20 0.35
PLAT P00750 1/20 0.35
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
AHR P35869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30467720 1.00 HTT (0.53) HTTCYP1A2CYP2C19BACE1PABPC1
SCHEMBL1543520 0.83 BACE1 (0.48) HTTCYP1A2CYP2C19BACE1PABPC1
SCHEMBL30008594 0.83 BACE1 (0.48) HTTCYP1A2CYP2C19BACE1PABPC1
SCHEMBL2616768 0.74 CYP1A2 (0.54) CYP1A2BACE1CYP2A6KDM4EALDH1A1
SCHEMBL22333813 0.74
SCHEMBL19014027 0.74 KDM4E (0.39) CYP1A2BACE1CYP2A6KDM4EALDH1A1
SCHEMBL277190 0.74 ALDH1A1 (0.53) CYP1A2KDM4EMEN1ALDH1A1KMT2A
SCHEMBL2006145 0.74 KMT2A (0.58) HTTKDM4EMEN1ALDH1A1MAPT
SCHEMBL277189 0.74
SCHEMBL28507119 0.74 NR4A2 (0.53) CYP1A2CYP2A6KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 VIVIDION THERAPEUTICS, INC. 2025-02-20 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
EP-2637660-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2013-09-18 EP disclosed
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2013-09-12 US disclosed
WO-2012064642-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 HTT 1359/4885CYP1A2 2977/4885CYP2C19 1687/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 HTT 1359/4885CYP1A2 2977/4885CYP2C19 1687/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 HTT 1359/4885CYP1A2 2977/4885CYP2C19 1687/4885
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 STAT3, JAK2, STAT1 HTT 2654/4885CYP1A2 4622/4885CYP2C19 4731/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH HTT 1417/4885CYP1A2 4150/4885CYP2C19 3592/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 HTT 462/4885CYP1A2 3838/4885CYP2C19 2842/4885
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 HTT 3758/4885CYP1A2 312/4885CYP2C19 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.